Baxalta US Inc. – FDA 483, Apr 7, 2022
An FDA inspection of Baxalta US Inc. in Thousand Oaks, CA, identified significant deficiencies in their manufacturing processes for sterile drug products. The firm's aseptic process validations, specifically media fills, were found to be inadequate, failing to accurately simulate commercial production conditions and interventions. Additionally, investigations into unexplained discrepancies and batch failures were insufficient, often not extending to other affected batches or being closed in a timely manner.
ID · 45fd3851-40ed-446c-8ca0-05c8cd0ca027
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.